New personalized treatment strategies in breast cancer

trastuzumab
Recently, Distinguished Professor of the Master of Molecular Oncology, Dr. Joaquín Arribas, has succeeded in designing a new therapy for the treatment of breast cancer.
Approximately 20% tumors of breast cancer have an overexpression of Her2. Tumors with this condition are treated with antibodies specifically designed against the extracellular domain of the receptor tyrosine kinase, HER2, as for the drug trastuzumab.

About 30% these Her2 positive breast cancers, the complete protein not overexpress, but a series of carboxy terminal fragments of HER2, called p95. These fragments are highly unstable and oncogenic, because they are capable of spontaneously homodimerize, creating a complex of Her2 constitutively active.
Initially, because these fragments were HER2 cytoplasmic, these tumors were thought to be resistant to trastuzumab. However, research by Dr. Arribas, described as the combined chemotherapy and trastuzumab significantly improved response in these patients.
This improvement is due to prior chemotherapy, sensitizes tumor cells, stabilizing oncogenic homodimers of p95Her2, and thus enhancing the effect of treatment with trastuzumab.
These observations were performed in cell lines and mice, and a clinical trial is needed to confirm the benefits of this combination therapy.